Loading...

Clinical trials in severe sepsis with drotrecogin alfa (activated)

Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Evaluation of Medical Products also recommended that DrotAA could be administered to patients w...

Full description

Saved in:
Bibliographic Details
Main Author: Laterre, Pierre-François
Format: Artigo
Language:Inglês
Published: BioMed Central 2007
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2230609/
https://ncbi.nlm.nih.gov/pubmed/18269692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/cc6156
Tags: Add Tag
No Tags, Be the first to tag this record!